SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 22, 2005
------------
SIGA TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-23047 13-3864870
(State or other jurisdiction of (Commission file number) (I.R.S. employer
incorporation or organization) identification no.)
420 Lexington Avenue, Suite 408
New York, New York 10170
(Address of principal executive offices) (Zip code)
Registrant's telephone number, including area code: (212) 672-9100
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of
the following provisions (see General Instruction A.2. below):
--------------------------------------------------------------------------------
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
On September 22, 2005, SIGA Technologies, Inc., a Delaware
corporation ("SIGA"), entered into a $3.2 million, one-year agreement with the
United States Army Medical Research and Material Command ("USAMRMC"). The
agreement, for the rapid identification and treatment of anti-viral diseases, is
funded through the United States Air Force ("USAF"). SIGA's efforts will aid the
USAF Special Operations Command in its use of computational biology to design
and develop specific countermeasures against the biological threat agents
Smallpox and Adenovirus. Smallpox is a Center for Disease Control and Prevention
(CDC) Category A biothreat agent, and Adenovirus is a cause of significant
respiratory infectious disease, both of which may impair the combat readiness of
USAF Personnel. A copy of the agreement is attached hereto as exhibit 10.1,
which is incorporated into this Item 1.01 by reference.
On September 27, 2005, SIGA issued a press release announcing that
it had entered into the agreement with USAMRMC. A copy of the press release is
attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
Exhibit No. Description
----------- -----------
10.1 Agreement, dated as of September 22, 2005, between the United
States Army Medical Research and Material Command and SIGA.
99.1 Press Release, dated September 27, 2005.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SIGA TECHNOLOGIES, INC.
By: /s/ Thomas N. Konatich
---------------------------------
Name: Thomas N. Konatich
Title: Chief Financial Officer
Date: September 27, 2005
3